Expertise in
57
conditions

Dr. Madhu Unnikrishnan

Oncology
University Medical Center
602 Indiana Ave, 
Lubbock, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
57
conditions
University Medical Center
602 Indiana Ave, 
Lubbock, TX 

Overview

Madhu Unnikrishnan is an Oncologist practicing medicine in Lubbock, Texas.

Dr. Unnikrishnan is highly rated in 57 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Colorectal Cancer, Lynch Syndrome, and Pleuropulmonary Blastoma.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 9 clinical trials. Dr. Unnikrishnan is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in AZ

Hospital Affiliations

Yuma Regional Medical Center
Providence Holy Family Hospital
Cleveland Clinic Indian River Hospital
University Medical Center
Baptist Health Paducah

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

University Medical Center
602 Indiana Ave, Lubbock, TX 79415
Other Locations
John P Petersen MD PA
3555 10th Ct, Vero Beach, FL 32960

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Other, Drug
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Biological
Study Drugs: Cabozantinib, Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
View 8 Less Clinical Trials

1 Total Publications

Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.
Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 19, 2015
Similar Doctors
Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

UMC Cancer Center

602 Indiana Ave, 
Lubbock, TX 
 (0.1 miles away)
806-775-8600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Hutson is an Oncologist practicing medicine in Lubbock, Texas. Dr. Hutson is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Hutson is currently accepting new patients.

Expertise in
54
conditions
Expertise in
54
conditions
Referral may be required
Before you request
4101 22nd Place, 
Lubbock, TX 
 (1.3 miles away)
806-725-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ibrahim Shalaby is an Oncologist practicing medicine in Lubbock, Texas. Dr. Shalaby is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma. Dr. Shalaby is currently accepting new patients.

Expertise in
54
conditions
Expertise in
54
conditions
Referral may be required
Before you request
4101 22nd Place, 
Lubbock, TX 
 (1.3 miles away)
806-725-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Close is an Oncologist practicing medicine in Lubbock, Texas. Dr. Close is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, and Familial Colorectal Cancer. Dr. Close is currently accepting new patients.

Frequently Asked Questions about Dr. Madhu Unnikrishnan

How do I make an appointment with Dr. Madhu Unnikrishnan?

You can book an appointment with Dr. Madhu Unnikrishnan by calling their office at 806-775-8200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Madhu Unnikrishnan a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Madhu Unnikrishnan is classified as an Distinguished expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Madhu Unnikrishnan specialize in?

While Dr. Madhu Unnikrishnan is a Oncology, they have specific expertise in Thrombocytopenia, Colorectal Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Madhu Unnikrishnan participate in research or clinical trials?

Yes. Dr. Madhu Unnikrishnan has published 1 articles and abstracts on conditions like Thrombocytopenia. You can view a list of Dr. Madhu Unnikrishnan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Madhu Unnikrishnan accept my insurance?

Dr. Madhu Unnikrishnan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 806-775-8200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Unnikrishnan's expertise for a condition
ConditionClose
    View All 51 Advanced Conditions
    View All 105 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile